VUB spin-off Camel-IDS collects 37m euros

Camel-IDS is a spin-off company of the VUB developing cancer-targeted radiopharmaceuticals. It secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland). Existing investors also participated. The proceeds will enable Camel-IDS to run a phase Ib/II trial with its lead program CAM-H2 targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.

Camel-IDS originated in 2015 from the Molecular Image Processing research group and the Department of Nuclear Medicine at UZ Brussel led by Prof. dr. Tony Lahoutte. Other researchers who contributed to the success of this spin-off are Geert Raes, Matthias D'Huyvetter, Nick Devoogdt and Jens De Vos.

Read more.